Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis | Zendy

Mari Carmen Torres-Moreno | Zendy; Esther Papaseit | Zendy; Marta Torrens | Zendy; Magı́ Farré | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis

Author(s) -

Mari Carmen Torres-Moreno,

Esther Papaseit,

Marta Torrens,

Magı́ Farré

Publication year - 2018

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2018.3485

Subject(s) - tolerability , medicine , placebo , adverse effect , spasticity , cochrane library , meta analysis , randomized controlled trial , anesthesia , analgesic , systematic review , physical therapy , medline , alternative medicine , pathology , political science , law

Key Points Question Are medicinal cannabinoids effective and well tolerated in the treatment of multiple sclerosis? Findings In this systematic review and meta-analysis of 17 randomized clinical trials including 3161 patients, cannabinoids were significantly associated with efficacy for subjective spasticity, pain, and bladder dysfunction compared with placebo. Cannabinoids had a higher risk of adverse events and withdrawals due to adverse events, with no statistically significant differences found for serious adverse events. Meaning Cannabinoids appear to be safe regarding serious adverse events, but their clinical benefit may be limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research